Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Signature Bank (NASDAQ: SBNY), Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), Steven Madden, Ltd. (NASDAQ: SHOO), Texas Capital (NASDAQ: TCBI), Webster Financial Corp. (NYSE: WBS) and Apollo Group, Inc. (NASDAQ: APOL) ratings and price targets.
Signature Bank (SBNY) is now covered by Deutsche Bank (NYSE:DB). They placed a “Buy” rating on the company.
Sagent Pharmaceuticals Inc. (SGNT) is now covered by Capstone Investments. They placed a “Buy” rating on the company.
Steven Madden, Ltd. (SHOO) is now covered by KeyBanc. They placed a “Hold” rating on the company.
Texas Capital (TCBI) is now covered by Deutsche Bank. They placed a “Hold” rating on the company.
Webster Financial Corp. (WBS) is now covered by Deutsche Bank. They placed a “Buy” rating on the company.
Alexion Pharmaceuticals, Inc. (ALXN) had its “Buy” rating reiterated by Goldman Sachs (NYSE:GS).
Apollo Group, Inc. (APOL) had its “Outperform” rating reiterated by Barrington Research.
Showing posts with label Alexion Pharmaceuticals. Show all posts
Showing posts with label Alexion Pharmaceuticals. Show all posts
Thursday, January 5, 2012
Friday, December 30, 2011
Alexion Pharmaceuticals (ALXN) Ratings, Price Targets
Updates on Alexion Pharmaceuticals (NASDAQ: ALXN) ratings and price targets.
Alexion Pharmaceuticals (NASDAQ: ALXN) had its “Outperform” rating reiterated by Leerink Swann.
Piper Jaffray (NYSE: PJC) cut their price target on Alexion Pharmaceuticals to $83.00.
Barclays Capital (NYSE: BCS) initiated coverage on Alexion Pharmaceuticals. They placed an “Overweight” rating and a price target of $77.00 on the company.
Morgan Stanley (NYSE: MS) raised their price target on Alexion Pharmaceuticals to $67.00 on October 24th.
Alexion closed Thursday at $70.98, up $0.06, or 0.08 percent.
Alexion Pharmaceuticals (NASDAQ: ALXN) had its “Outperform” rating reiterated by Leerink Swann.
Piper Jaffray (NYSE: PJC) cut their price target on Alexion Pharmaceuticals to $83.00.
Barclays Capital (NYSE: BCS) initiated coverage on Alexion Pharmaceuticals. They placed an “Overweight” rating and a price target of $77.00 on the company.
Morgan Stanley (NYSE: MS) raised their price target on Alexion Pharmaceuticals to $67.00 on October 24th.
Alexion closed Thursday at $70.98, up $0.06, or 0.08 percent.
Thursday, December 29, 2011
Alexion (ALXN) (MLNX) (OFC) (PKE) (SNTS) (HOLI) Ratings, Price Targets
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Mellanox Technologies, Ltd. (NASDAQ: MLNX), Corp. Office Properties (NYSE: OFC), Park Electrochemical Corp. (NYSE: PKE), Santarus (NASDAQ: SNTS) and Hollysys Automation Technologies Ltd (NASDAQ: HOLI) ratings and price targets.
Alexion Pharmaceuticals, Inc. (ALXN) had its “Outperform” rating reiterated by Leerink Swann.
Mellanox Technologies, Ltd. (MLNX) is now covered by Wunderlich. They have a “Hold” rating and a price target of $36.00 on the firm.
Corp. Office Properties (OFC) was downgraded by Zacks Investment Research from a “Neutral” rating to an “Underperform” rating.
Park Electrochemical Corp. (PKE) was downgraded by Zacks Investment Research from a “Neutral” rating to an “Underperform” rating.
Santarus (SNTS) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
Hollysys Automation Technologies Ltd (HOLI) was upgraded by Roth Capital from a “Neutral” rating to a “Buy” rating.
Alexion Pharmaceuticals, Inc. (ALXN) had its “Outperform” rating reiterated by Leerink Swann.
Mellanox Technologies, Ltd. (MLNX) is now covered by Wunderlich. They have a “Hold” rating and a price target of $36.00 on the firm.
Corp. Office Properties (OFC) was downgraded by Zacks Investment Research from a “Neutral” rating to an “Underperform” rating.
Park Electrochemical Corp. (PKE) was downgraded by Zacks Investment Research from a “Neutral” rating to an “Underperform” rating.
Santarus (SNTS) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
Hollysys Automation Technologies Ltd (HOLI) was upgraded by Roth Capital from a “Neutral” rating to a “Buy” rating.
Friday, July 22, 2011
eBay (EBAY) (EMC) (FFIV) (ESI) (ALXN) Price Targets Changed
eBay, Inc. (NASDAQ: EBAY), EMC Corp. (NYSE: EMC), F5 Networks (NASDAQ: FFIV), ITT Educational Services Inc (NYSE: ESI) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) had their price targets adjusted by analysts.
Alexion Pharmaceuticals (ALXN) had its price target raised by Brean Murray from $57.00 to $60.00. They have a “buy” rating on the company.
eBay, Inc. (EBAY) had its price target raised by Barclays Capital from $36.00 to $38.00. They have an “equal weight” rating on the company.
EMC Corp. (EMC) had its price target raised by Barclays Capital from $35.00 to $37.00. They have an “overweight” rating on the company.
ITT Educational Services (ESI) had its price target raised by Barclays Capital from $91.00 to $100.00. They have an “equal weight” rating on the company.
F5 Networks (NASDAQ: FFIV) had its price target lowered by Barclays Capital from $125.00 to $118.00. They have an “overweight” rating on the company.
Alexion Pharmaceuticals (ALXN) had its price target raised by Brean Murray from $57.00 to $60.00. They have a “buy” rating on the company.
eBay, Inc. (EBAY) had its price target raised by Barclays Capital from $36.00 to $38.00. They have an “equal weight” rating on the company.
EMC Corp. (EMC) had its price target raised by Barclays Capital from $35.00 to $37.00. They have an “overweight” rating on the company.
ITT Educational Services (ESI) had its price target raised by Barclays Capital from $91.00 to $100.00. They have an “equal weight” rating on the company.
F5 Networks (NASDAQ: FFIV) had its price target lowered by Barclays Capital from $125.00 to $118.00. They have an “overweight” rating on the company.
Tuesday, May 17, 2011
Ratings on (ADI) (ALXN) (AMD) (ANF) (BEXP) Reiterated
Ratings on Analog Devices, Inc. (NYSE: ADI), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Advanced Micro Devices (NYSE: AMD), Abercrombie & Fitch (NYSE: ANF) and Brigham Exploration (NASDAQ: BEXP) were reiterated by analysts.
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “overweight” rating on Analog Devices, Inc. (ADI).
Goldman Sachs (NYSE:GS) reiterated a “buy” rating on Alexion Pharmaceuticals, Inc. (ALXN). They have a price target of $112.00 on the company.
Sterne Agee reiterated a “buy” rating on Advanced Micro Devices (AMD). They have a price target of $15.00 on the company.
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Abercrombie & Fitch (ANF). They have a price target of $85.00 on the company.
Global Hunter Securities reiterated an “accumulate” rating on Brigham Exploration (BEXP).
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “overweight” rating on Analog Devices, Inc. (ADI).
Goldman Sachs (NYSE:GS) reiterated a “buy” rating on Alexion Pharmaceuticals, Inc. (ALXN). They have a price target of $112.00 on the company.
Sterne Agee reiterated a “buy” rating on Advanced Micro Devices (AMD). They have a price target of $15.00 on the company.
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Abercrombie & Fitch (ANF). They have a price target of $85.00 on the company.
Global Hunter Securities reiterated an “accumulate” rating on Brigham Exploration (BEXP).
Monday, May 9, 2011
Big Movers (HOC) (NTAP) (ALXN) (ARMH) (THOR) on May 6
Among the big, positive movers on Friday, May 6, were Holly Corp. (HOC), Netapp (NTAP), Alexion Pharmaceutic (ALXN), Arm Holdings Plc (ARMH) and Thoratec Corp. (THOR).
Holly Corp. (HOC) jumped $1.81, to close at $55.55, a gain of 3.37 percent.
Netapp (NTAP) was up $1.80 on the day to close at $53.30, a gain of 3.50 percent.
Alexion Pharmaceutic (ALXN) climbed $1.76 to close at $95.89, a gain of 1.87 percent.
Arm Holdings Plc (ARMH) rose $1.76 to close the session at $29.27, a gain of 6.40 percent.
Thoratec Corp. (THOR) was up $1.76 to end the day at $33.58, a gain of 5.53 percent.
Holly Corp. (HOC) jumped $1.81, to close at $55.55, a gain of 3.37 percent.
Netapp (NTAP) was up $1.80 on the day to close at $53.30, a gain of 3.50 percent.
Alexion Pharmaceutic (ALXN) climbed $1.76 to close at $95.89, a gain of 1.87 percent.
Arm Holdings Plc (ARMH) rose $1.76 to close the session at $29.27, a gain of 6.40 percent.
Thoratec Corp. (THOR) was up $1.76 to end the day at $33.58, a gain of 5.53 percent.
Tuesday, February 1, 2011
Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN), Human Genome (NASDAQ:HGSI) Could be Takeover Targets
With time and costs a major factor in the drug industry, companies appear to be hunting for takeover targets like Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI), which have a pipeline, or are close to developing a pipeline, with soon-to-be-approved drugs.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Thursday, January 6, 2011
Alexion Pharmaceuticals (NASDAQ:ALXN) Should Follow 2010 with Another Strong year
Citing the continued strong growth in sales of Soliris and the results of aHUS, Needham believes Alexion Pharmaceuticals (NASDAQ:ALXN) should be considered a stock of interest in 2011.
Needham said, "The highlights of the 2010 Season of Biotech (Sep-Dec) for Alexion Pharmaceuticals were the continued strong growth of Soliris sales as well as the impressive results in aHUS that may provide a significant label expansion opportunity for Soliris. We view ALXN as a stock of added interest in 2011...We believe that ALXN stock is of added interest to investors focusing on mid-cap, revenue-generating biotech names."
Needham & Company reiterates a "Buy" rating on Alexion Pharmaceuticals, which closed Wednesday at $82.76, gaining $1.29, or 1.58 percent.
Needham said, "The highlights of the 2010 Season of Biotech (Sep-Dec) for Alexion Pharmaceuticals were the continued strong growth of Soliris sales as well as the impressive results in aHUS that may provide a significant label expansion opportunity for Soliris. We view ALXN as a stock of added interest in 2011...We believe that ALXN stock is of added interest to investors focusing on mid-cap, revenue-generating biotech names."
Needham & Company reiterates a "Buy" rating on Alexion Pharmaceuticals, which closed Wednesday at $82.76, gaining $1.29, or 1.58 percent.
Tuesday, November 23, 2010
Alexion (NASDAQ:ALXN) Waiting on Soliris
The promising potential of of Soliris in aHUS can't be included in the analysis of Alexion Pharmaceuticals (NASDAQ:ALXN) at this time, as there are still several steps to go through before it will be known if it'll be part of their product line.
Here's Needham's take on Soliris and Alexion:
"We are impressed by the efficacy of Soliris in this difficult-to-treat aHUS population, with no currently effective therapeutic options. We believe Soliris may have the potential to affect the underlying disease process and lead to better health outcomes and improved quality of life for these patients. Alexion is also conducting a pediatric study that may make Soliris available early in aHUS patients’ lives. With strong aHUS data in hand, we believe the Company is in discussion with the FDA regarding the regulatory pathway for Soliris for the aHUS indication. We await further updates on these discussions before we include the aHUS opportunity in our ALXN valuation."
Needham maintains their "Buy" rating on Alexion Pharmaceuticals. They closed Monday at $75.98, gaining $0.98, or 1.31 percent. Needham has a price target of $76 on them.
Here's Needham's take on Soliris and Alexion:
"We are impressed by the efficacy of Soliris in this difficult-to-treat aHUS population, with no currently effective therapeutic options. We believe Soliris may have the potential to affect the underlying disease process and lead to better health outcomes and improved quality of life for these patients. Alexion is also conducting a pediatric study that may make Soliris available early in aHUS patients’ lives. With strong aHUS data in hand, we believe the Company is in discussion with the FDA regarding the regulatory pathway for Soliris for the aHUS indication. We await further updates on these discussions before we include the aHUS opportunity in our ALXN valuation."
Needham maintains their "Buy" rating on Alexion Pharmaceuticals. They closed Monday at $75.98, gaining $0.98, or 1.31 percent. Needham has a price target of $76 on them.
Subscribe to:
Posts (Atom)